Inpharma Weekly

, Volume 1146, Issue 1, pp 7–8 | Cite as


a natural successor to fluconazole?
  • David Jack
Newsletter Article


Despite the large number of antifungal agents currently available, very few are effective against life-threatening mycoses. In particular, the management of aspergillosis is a therapeutic challenge because of difficulties in diagnosing the infection, and the limited number of well tolerated drugs that are active in vivo against Aspergillus species, says Professor Glyn Evans from the University of Leeds, UK. His comments were directed at delegates attending a Pfizer-sponsored symposium on its latest broad-spectrum antifungal, voriconazole * , held during the 4th Congress of the European Confederation of Medical Mycology [ Glasgow, Scotland; May 1998 ].


Fluconazole Itraconazole Voriconazole Aspergillosis Candida Species 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1998

Authors and Affiliations

  • David Jack

There are no affiliations available

Personalised recommendations